Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19

Benzinga · 1d ago
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from $20 to $19.